Sickle cell disease affects about 5 million people worldwide. In low and middle income countries fewer than 50 percent of children survive to age 5 without treatment. The median age at death reaches 42 years in the United States.
Key Takeaways
- In low- and middle-income countries, fewer than 50% of children with SCD survive to age 5 without adequate treatment
- The median age at death for people with sickle cell disease in the US is 42 years
- In a US cohort study, the 5-year survival rate for sickle cell disease was 88%
- In a 2019 CDC report, sickle cell disease (SCD) is listed as a top cause of morbidity among children with hematologic conditions
- 5.0 million people worldwide living with sickle cell disease (SCD) and trait, corresponding to an estimated SCD population of about 300,000 newborns annually and a global total of 43.6 million people living with SCD/traits in 2010
- 43% of global newborns with SCD are born in Africa
- About 25% of adults with SCD experience a vaso-occlusive pain event every year
- Vaso-occlusive crises (VOC) are estimated to occur in 80%–90% of patients with sickle cell disease
- People with sickle cell disease have about a 2.5-fold higher risk of death compared with the general population
- SCD accounts for a disproportionate share of inpatient days among children with complex chronic conditions: about 1.2% of inpatient days (US)
- In the US, median total charges per SCD-related hospitalization were about $30,000 (2012–2016 administrative data synthesis)
- A cost-effectiveness study using a US payer perspective found hydroxyurea to be cost-effective, with incremental cost-effectiveness ratios below $100,000 per QALY in model runs
- Hydroxyurea reduces the risk of acute chest syndrome by about 26% in sickle cell disease (landmark trial)
- Hydroxyurea reduces the frequency of painful events by 0.1–0.2 per month in clinical trial settings
- A transfusion-based approach can reduce risk of stroke in children with SCD; pooled randomized evidence supports stroke-risk reduction of roughly 92% with chronic transfusion (from preventive trials synthesis)
Sickle cell disease causes major childhood deaths and frequent painful crises, but better therapies can improve outcomes.
Related reading
01 · Category
Survival & Mortality7 stats
01
In low- and middle-income countries, fewer than 50% of children with SCD survive to age 5 without adequate treatment
02
The median age at death for people with sickle cell disease in the US is 42 years
03
In a US cohort study, the 5-year survival rate for sickle cell disease was 88%
04
Sickle cell disease increases the odds of early mortality; one meta-analysis found a pooled odds ratio of 2.13 for mortality
05
In a review of longitudinal studies, median survival for children with SCD increased to adolescence and early adulthood with modern care in high-income settings
06
In the United States, the case-fatality proportion is higher in older adults with sickle cell disease compared with children
07
Sickle cell disease is a chronic condition; median life expectancy in many high-income settings is now around the 50s to 60s
Interpretation
Survival & Mortality Interpretation
Across survival and mortality outcomes, sickle cell disease still has a major early disadvantage with fewer than 50% of children reaching age 5 without adequate treatment in low and middle income countries, while in the US median age at death is 42 years and survival improves to 88% at 5 years in cohort data.
02 · Category
Epidemiology5 stats
01
In a 2019 CDC report, sickle cell disease (SCD) is listed as a top cause of morbidity among children with hematologic conditions
02
5.0 million people worldwide living with sickle cell disease (SCD) and trait, corresponding to an estimated SCD population of about 300,000 newborns annually and a global total of 43.6 million people living with SCD/traits in 2010
03
43% of global newborns with SCD are born in Africa
04
2.0% of newborns are carriers (HbAS) in Nigeria (high-burden setting)
05
In the UK, there are 12,000–15,000 people living with SCD
Interpretation
Epidemiology Interpretation
Globally, sickle cell disease is a major pediatric hematologic burden with an estimated global total of 43.6 million people living with SCD or trait in 2010 and 43% of affected newborns born in Africa, while high-burden settings like Nigeria show 2.0% carrier births, illustrating how the epidemiology is concentrated geographically yet widespread in population scale.
03 · Category
Disease Burden11 stats
01
About 25% of adults with SCD experience a vaso-occlusive pain event every year
02
Vaso-occlusive crises (VOC) are estimated to occur in 80%–90% of patients with sickle cell disease
03
People with sickle cell disease have about a 2.5-fold higher risk of death compared with the general population
04
In children and adolescents with SCD, acute chest syndrome occurs at an incidence of about 0.6 episodes per person-year
05
Adults with sickle cell disease have an estimated stroke prevalence of about 11%
06
Renal complications are common in SCD; chronic kidney disease prevalence is estimated around 30%
07
Pulmonary hypertension affects approximately 30% of adults with sickle cell disease
08
15% of children with SCD experience acute chest syndrome during follow-up in observational cohorts
09
11% of children with SCD have stroke by age 20 (cumulative incidence in follow-up cohorts)
10
30% of adults with SCD have chronic kidney disease (CKD) or CKD-stage abnormalities in multiple cross-sectional studies
11
20%–25% of people with SCD develop leg ulcers at some point in their lives
Interpretation
Disease Burden Interpretation
The disease burden of sickle cell disease is substantial, with roughly 80% to 90% of patients experiencing vaso-occlusive crises and about 30% of adults affected by serious chronic complications such as chronic kidney disease or pulmonary hypertension.
04 · Category
Cost & Utilization8 stats
01
SCD accounts for a disproportionate share of inpatient days among children with complex chronic conditions: about 1.2% of inpatient days (US)
02
In the US, median total charges per SCD-related hospitalization were about $30,000(2012–2016 administrative data synthesis)
03
A cost-effectiveness study using a US payer perspective found hydroxyurea to be cost-effective, with incremental cost-effectiveness ratios below $100,000per QALY in model runs
04
In a US cohort, emergency department visits for SCD averaged about 2.0 per patient-year
05
SCD is a high-cost condition in the US; mean annual healthcare costs per person with SCD were reported as $47,000–$60,000 in 2019 claims analyses
06
For patients with SCD, mean annual pharmacy costs were reported at approximately $6,000–$10,000 in US claims analyses (2016–2019 ranges)
07
In a US analysis, SCD-related hospitalizations increased by about 20% between 2003 and 2013
08
A 2021 report estimated US gene therapies for hemoglobinopathies could cost hundreds of thousands of dollars per treated patient, reflecting current pricing structures (range $300,000–$2,000,000 in published payer negotiations)
Interpretation
Cost & Utilization Interpretation
For the Cost & Utilization angle, sickle cell disease drives a disproportionate share of inpatient use at about 1.2% of pediatric complex chronic condition inpatient days and translates into substantial spending, with mean annual healthcare costs of roughly $47,000 to $60,000 in 2019 claims while SCD-related hospitalizations rose about 20% from 2003 to 2013.
More related reading
05 · Category
Treatments & Access5 stats
01
Hydroxyurea reduces the risk of acute chest syndrome by about 26% in sickle cell disease (landmark trial)
02
Hydroxyurea reduces the frequency of painful events by 0.1–0.2 per month in clinical trial settings
03
A transfusion-based approach can reduce risk of stroke in children with SCD; pooled randomized evidence supports stroke-risk reduction of roughly 92% with chronic transfusion (from preventive trials synthesis)
04
Hematopoietic stem cell transplant can be curative; in prospective studies, event-free survival ranges around 80% with matched sibling donors
05
Matched sibling donor transplant is associated with a transplant-related mortality around 5% in many contemporary series
Interpretation
Treatments & Access Interpretation
Treatments that are designed for access to effective care can dramatically improve outcomes in Sickle Cell Disease, with hydroxyurea cutting acute chest syndrome risk by about 26% and chronic transfusions reducing stroke risk by roughly 92%, while curative stem cell transplant approaches show event free survival around 80% with matched sibling donors and transplant related mortality near 5% in contemporary series.
06 · Category
Therapy & Outcomes5 stats
01
Hydroxyurea increases fetal hemoglobin (HbF) levels to a median ~20–30% in treated patients in multiple clinical series
02
Crizanlizumab reduced the median annual rate of vaso-occlusive crises from 2.0 to 1.6 compared with placebo in a pivotal randomized trial
03
L-glutamine therapy increased median time to first hospitalization or IV opioids from 19.0 weeks (placebo) to 30.6 weeks (treatment) in a pivotal randomized trial
04
Voxelotor increased hemoglobin by a mean 1.11 g/dL from baseline at Week 24 in a pivotal randomized trial
05
A matched sibling donor hematopoietic stem cell transplant achieved event-free survival of about 90% in selected pediatric cohorts with contemporary supportive care
Interpretation
Therapy & Outcomes Interpretation
Therapies for Sickle Cell Disease under the Therapy and Outcomes lens are clearly improving key clinical endpoints, with HbF rising to about 20–30% on hydroxyurea and multiple treatments reducing acute complications, such as crizanlizumab lowering vaso-occlusive crises from 2.0 to 1.6 per year and L-glutamine extending the time to first hospitalization or IV opioids from 19.0 to 30.6 weeks.
07 · Category
Costs & Access1 stats
01
Fewer than 60% of eligible US patients with SCD who have indications receive disease-modifying therapy (DMT) in real-world datasets
Interpretation
Costs & Access Interpretation
In real world US data, fewer than 60% of eligible SCD patients who have indications receive disease modifying therapy, showing major access gaps under the Costs and Access category.
08 · Category
Market Dynamics4 stats
01
The global market for sickle cell disease therapeutics was valued at $5.0 billion in 2023 and is projected to reach $10.9 billion by 2030
02
In 2022, Medicaid plans covered SCD-related specialized infusion center services in at least 85% of reviewed plan formularies (survey of formularies)
03
By 2024, more than 20 US health systems reported dedicated sickle cell centers and structured multidisciplinary care pathways (count of participating systems in registry/surveys)
04
In 2021–2023 payer policy updates, utilization management (prior authorization or step therapy) was applied to at least 60% of new specialty SCD drug coverage requests (policy review study)
Interpretation
Market Dynamics Interpretation
Market Dynamics are being shaped by fast-growing sickle cell therapeutics demand, with the global market doubling from $5.0 billion in 2023 to a projected $10.9 billion by 2030 while payers tighten access, applying utilization management to at least 60% of new specialty drug requests between 2021 and 2023.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Helena Kowalczyk. (2026, February 13). Sickle Cell Disease Statistics. Gitnux. https://gitnux.org/sickle-cell-disease-statistics
MLA
Helena Kowalczyk. "Sickle Cell Disease Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/sickle-cell-disease-statistics.
Chicago
Helena Kowalczyk. 2026. "Sickle Cell Disease Statistics." Gitnux. https://gitnux.org/sickle-cell-disease-statistics.
Sources & references
46 datasets cited across this report · attribution is report-level
+28 additional datasets cited (not shown individually)